Neurocrine Bioscience buy The Goldman Sachs Group, Inc.
Start price
25.01.24
/
50%
€128.55
Target price
25.01.25
€140.87
Performance (%)
9.80%
End price
26.01.25
€141.15
Summary
This prediction ended on 26.01.25 with a price of €141.15. The BUY prediction by The_Goldman_Sachs_Gr finished with a performance of 9.80%. The_Goldman_Sachs_Gr has a follow-up prediction for Neurocrine Bioscience where he still thinks Neurocrine Bioscience is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Neurocrine Bioscience | 0.629% | 0.629% | 25.729% |
| iShares Core DAX® | 0.411% | 8.821% | 12.264% |
| iShares Nasdaq 100 | 3.678% | 10.820% | 44.017% |
| iShares Nikkei 225® | 2.701% | 15.247% | 48.041% |
| iShares S&P 500 | 2.445% | 7.933% | 32.998% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Neurocrine Bioscience diskutieren
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $134.00 to $153.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
In the thread Trading Neurocrine Bioscience
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by The_Goldman_Sachs_Gr for Neurocrine Bioscience
Neurocrine Bioscience
Start price
Target price
Perf. (%)
€114.40
10.07.25
10.07.25
€154.99
10.07.26
10.07.26
-2.05%
22.04.26
22.04.26
